Target intelligence / Profile preview

ATP-dependent RNA helicase DDX51 (DDX51)

Target
DDX51
Molecular classification
Enzyme (RNA helicase), DEAD-box protein family
01

Overview

ATP-dependent RNA helicase DDX51 is an enzyme from the DEAD-box family involved in the processing and maturation of ribosomal RNAs, particularly the 28S rRNA, and the assembly of the 60S ribosomal subunit. Like other DEAD-box helicases, DDX51 acts by remodeling RNA structures or RNA–protein interactions through ATP hydrolysis, facilitating critical steps in RNA metabolism. DDX51 is ubiquitously expressed and is essential for ribosomal assembly and overall cell physiology. Elevated DDX51 expression has been reported in cancers such as esophageal squamous cell carcinoma, where it promotes cell proliferation, migration, invasion, and is correlated with poor clinical outcomes; it exerts part of its oncogenic effect by activating the PI3K/AKT signaling pathway. Currently, no drugs are known to specifically target DDX51, but as a member of the broader DEAD-box helicase family, it represents an emerging area of therapeutic research.

Other names
DEAD-box helicase 51DEAD box protein 51DEAD (Asp-Glu-Ala-Asp) box polypeptide 51DDX51
02

Mechanism of action

For the protein: unwinds RNA and modulates RNA–protein interactions in an ATP-dependent manner, particularly involved in ribosome biogenesis and rRNA maturation For potential drugs: Not established

03

Biological functions

rRNA processing (specifically, 3′ end maturation of 28S rRNA)Ribosome biogenesis (especially 60S ribosomal subunit assembly)RNA metabolism (unwinding or remodeling RNA and RNA–protein complexes)Modulation of ribonucleoprotein (RNP) structure and dynamics
04

Disease associations

Cancer (notably, esophageal squamous cell carcinoma: promotes proliferation, migration, invasion, and reduces apoptosis; associated with poor prognosis and advanced disease stage)Potentially other cancers via dysregulation of RNA processing, but the clearest evidence is in esophageal squamous cell carcinoma
05

Safety considerations

Targeting DDX51 or similar DEAD-box helicases could impact global RNA processing and ribosome biogenesis, possibly causing broad cellular effects or toxicity due to their essential role in housekeeping RNA metabolism
06

Interacting drugs

No direct small-molecule drugs are currently known to specifically target DDX51. DEAD-box RNA helicases as a family are emerging drug targets, but no DDX51-specific regulators or inhibitors are reported in the literature as of 2024
07

Biomarkers

High DDX51 expression in tumor tissues (esophageal squamous cell carcinoma) is a marker of poor prognosis, lower tumor differentiation, lymph node metastasis, and advanced cancer stage

Beyond the preview

Go deeper on ATP-dependent RNA helicase DDX51 (DDX51).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-dependent RNA helicase DDX51 (DDX51).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call